Filters

Pp-185 manufacturers

Filters

None products found

pp-185

Solution for infusion

Dossier type
CTD
Dossier status
Under development
Country of origin
South Korea
GMP approvals
PICS
Comments
Indication: Acute myeloid leukaemia (AML) with measurable residual disease (MRD+) after allogeneic haematopoietic stem cell transplantation (HSCT) Clinical stage: Phase 2 — ongoing Modality: Biological (allogeneic memory natural killer cell therapy — off-the-shelf) Mechanism / Target: Ex vivo-expanded allogeneic memory NK cells; leverages NK cell memory-like properties for enhanced and sustained anti-leukaemia activity against MRD+ residual blasts post-transplant Route / form: IV infusion Differentiation: First allogeneic memory NK cell therapy in clinical development for AML MRD+; off-the-shelf manufacturing (no patient-specific product); addresses high-risk MRD+ relapse post-HSCT with no approved treatment
Manufacturer #39326
South Korean biotech founded in 2020 developing clinical-stage Rx NK cell-based anti-cancer immunotherapies for solid and hematologic tumors. Lead injectable biologic program holds FDA Orphan Drug designation for acute myeloid leukemia. Advances global development through clinical trials and international regulatory engagements.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.